Good morning :)
Place Order
Add to Watchlist

IND Swift Laboratories Ltd

INDSWFTLAB

IND Swift Laboratories Ltd

INDSWFTLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹767 cr, stock is ranked 1,470
High RiskStock is 5.71x as volatile as Nifty
129.953.09% (+3.90)
129.953.09% (+3.90)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹767 cr, stock is ranked 1,470
High RiskStock is 5.71x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹767 cr, stock is ranked 1,470
High RiskStock is 5.71x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
17.781.13
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.965.950.56%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Ind-Swift Laboratories Limited is a company focused on the development of active pharmaceutical ingredients (APIs).

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 9.62%, vs industry avg of 8.36%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.39% to 0.38%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 16.73%, vs industry avg of 9.82%

Loading...

Financial YearFY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023TTM
Total Revenue682.83667.85737.46784.01876.44813.04914.041,082.231,240.811,222.13
Raw Materialssubtract393.23352.08377.52374.40421.46409.10457.35581.87673.70977.10
Power & Fuel Costsubtract34.7822.6526.7530.7039.1536.4038.8460.2777.84
Employee Costsubtract54.7366.8569.6588.1297.63102.72106.55127.09135.84
Selling & Administrative Expensessubtract52.2755.3663.1981.2162.1074.8979.1662.8063.65
Operating & Other expensessubtract89.6062.5279.0258.7810.1812.1526.6211.0853.73
Depreciation/Amortizationsubtract84.2984.7588.2686.62104.0590.0687.29131.0457.3649.93
Interest & Other Itemssubtract117.29106.4288.3728.2192.20107.49100.2295.5592.1784.39
Taxes & Other Itemssubtract-23.98-24.10-16.1614.0120.731.4221.1614.6838.9267.53
EPS-29.76-14.33-9.124.866.21-3.96-0.53-0.368.037.29
DPS0.000.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

Nov 18PDF
Jul 31PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
IND Swift Laboratories Ltd16.131.13
Sun Pharmaceutical Industries Ltd43.616.230.75%
Cipla Ltd40.254.760.61%
Dr Reddy's Laboratories Ltd22.484.350.66%

Price Comparison

Compare INDSWFTLAB with any stock or ETF
Compare INDSWFTLAB with any stock or ETF
INDSWFTLAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding

Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding42.00%0.00%18.73%0.31%38.95%

Mar 2023

Jun 2023

Sep 2023

Dec 2023

Shareholding History

SepDec '22MarJunSepDec '230.00%0.04%0.00%0.08%0.17%0.31%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

INDSWFTLAB has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 20, 2011

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 20, 2011

Cash Dividend

Ex DateEx DateSep 16, 2010

Final
Final | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Sep 16, 2010